News:
August 14, 2008
Nephros Reports Second Quarter 2008 Financial Results
Click here for additional information
July 14, 2008
Nephros Exhibiting at Maryland ASHE Conference July 20-23, 2008
Click here for additional information
June 5, 2008
Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
Click here for additional information
June 2, 2008
Nephros exhibiting at Denver, Colorado APIC Conference
June 15-19, 2008
Click here for additional information
May 15, 2008
Nephros Reports First Quarter 2008 Financial Results
Click here for additional information
May 10, 2008
Nephros to Exhibit at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008
Click here for additional information
April 29, 2008
Nephros Appoints Gerald J. Kochanski as Chief Financial Officer
Click here for additional information
April 21, 2008
Nephros Strengthens Commercialization Team with Addition of Marketing Executive
Click here for additional information
March 31, 2008
Nephros Reports 2007 Fourth Quarter and Full Year Financial Results
Click here for additional information
January 16, 2008
Nephros, Inc. Substantially Increases Stockholders' Equity and Expects to Regain Compliance With the American Stock Exchange Continued Listing
Click here for additional information
December 19, 2007
Department of Defense Appropriations Act 2008 Provides $2 Million for Continued Development of Nephros Dual Stage Ultra Reliable Filter
Click here for additional information
November 20, 2007
Nephros Appoints James S. Scibetta to Board of Directors
Click here for additional information

Nephros Receives Approval to Market OLpur™ MD Hemodiafilter Series in Canada
Click here for additional information
November 13, 2007
Nephros Reports Third Quarter 2007 Financial Results
Click here for additional information
October 16, 2007
Nephros Initiates Pivotal U.S. Trial for OLpur™ H2H™ Hemodiafiltration Module and OLpur™ MD 220 Hemodiafilter
Click here for additional information
October 3, 2007
Nephros Receives Non-Compliance Notification from Amex
Click here for additional information
September 25, 2007
Nephros Raises $12.7 Million in New Financing
Click here for additional information
August 13, 2007
Nephros Reports Second Quarter 2007 Financial Results
Revenues Increase 15%, Net Loss is Reduced
Click here for additional information
August 7, 2007
Nephros Discloses Nonpayment of Installment under the Lancer Settlement Agreement in Current Report on Form 8-K
Click here for additional information
July 20, 2007
Nephros Names New Independent Auditing Firm
Click here for additional information
May 23, 2007
Nephros Reports Departure of Director
Click here for additional information
May 16, 2007
Nephros to Initiate U.S. Clinical Trials
Click here for additional information
May 15, 2007
Nephros Reports First Quarter 2007 Financial Results
Revenues Increase 70%, Net Loss is Reduced
Click here for additional information
May 3, 2007
Nephros Provides Information Regarding Auditor's Going Concern Report and Fiscal 2006 Results
Click here for additional information
May 1, 2007
Nephros Reports Departure of Director
Click here for additional information
March 1, 2007
Nephros Completes Informational Request from the FDA
on Investigational Device Exemption Application

Nephros MD and H2H Technologies Clinical Trials Expected to Commence in March 2007
Click here for additional information
January 29, 2007
Nephros Receives Conditional Approval from the FDA
of Investigational Device Exemption Application

Nephros MD and H2H Technologies Targeted to Begin Clinical Trials in First Quarter 2007
Click here for additional information
Nephros can be found on the American Stock Exchange under the ticker symbol NEP. Click here for additional information.

Dialysis Industry Meetings

  • Nov 4 - 9, 2008
    American Society of Nephrology (ASN) Renal Week
    Philadelphia, PA

2009 Meetings

  • Mar 8 - 10, 2009
    International Dialysis Conference
    Houston, TX
  • Mar 20 - 23, 2009
    Renal Physicians Associates
    Baltimore, MD
  • Mar 25 - 29, 2009
    National Kidney Foundation Spring
    Gaylord Nashville, TN
  • Apr 26 - 29, 2009
    American Nephrology Nurses Association
    San Diego, CA
  • August 2009
    American Association of Kidney Patients
    Tampa, FL
  • Oct 27 - Nov 1, 2009
    American Society of Nephrology Renal Week
    San Diego, CA

Water Industry Meetings

  • Oct 2 - 5, 2008
    American Society of Healthcare Risk Management
    Boston, MA
  • Jul 20 - 23, 2008
    American Society of Healthcare Engineering (ASHE) of the American Hospital Association (AHA)
    Washington, DC / Booth #839
  • Jun 15 - Jun 19, 2008
    APIC 2008
    Denver, CO

2009 Meetings

  • Mar 17 - 21, 2009
    WQA Aquatech
    Chicago, IL
  • Mar 19 - 22, 2009
    SHEA
    San Diego, CA
  • Jun 7 - 11, 2009
    APIC
    Florida
  • August 2009
    Society of Health Engineers
    Philadelphia, PA
  • Oct 22 -25, 2009
    American Society of Healthcare Risk Management (ASHRM)
    Denver, CO

The Future of ESRD Therapy
Nephros, Inc. has developed new system technologies and companion products that will improve survival, increase the quality of life, and reduce medical costs for patients with End Stage Renal Disease (ESRD). The Company has developed unique and proprietary technologies that address the major overriding needs of ESRD treatment by providing:

Significant improvement in treatment efficacy, particularly with respect to the removal of many harmful substances, such as the "middle molecule" beta-2-microglobulin, not effectively removed by current dialytic methods.

Cost effective therapies that provide a better life for the patient while meeting the business needs of the clinic.
     
© 2007 Nephros, Inc.